59 results about "Tamsulosin hydrochloride" patented technology

The invention provides double-layer osmotic pump tablets of tamsulosin ehydrochloride and a process for preparation. The medicament contains tamsulosin ehydrochloride and acceptable medical polymeric excipient, and is characterized in that the invention has excellent zero-level controlled releasing, pH level of environment, movements of the stomach and intestine, and food, has little effect on releasing action and food, and has no effect on the internal pharmacokinetics parameter. According to the percentage by weight, the preparation contains tamsulosin ehydrochloride 0-2%, excipient in pastille layer with the function of controlled-releasing 30-70% excipient in boosting layer with the function of controlled releasing 30-70%, and the rest percentage of other excipient. The of process for preparation the double layer permeable pump controlled-release tablets of tamsulosin ehydrochloride comprises (1) the preparation of pastille layer, (2) the preparation of boosting layer, (3) the compressing of the two layers, (4) the coating of the double layer tablets, (5) the perforating of the coated tablets, (6) the packing of moisture proof cost. The invention is clinically used for the treatment of paruria symptom like frequent micturition, diuresis at night, dysuria caused by prostatic hyperplasia.

The invention relates to a rectal administration composition containing tamsulosin, which comprises effective quantities of tamsulosin or pharmaceutically acceptable salts or derivatives thereof, solubilizer and sorbefacient, wherein the effective quantity of tamsulosin or pharmaceutically acceptable salts or derivatives thereof is metered according to the equivalence tamsulosin hydrochloride; the content of the tamsulosin or pharmaceutically acceptable salts or derivatives thereof is equivalent to 0.025-1.6 mg of tamsulosin hydrochloride; and the preparation per unit weighs 0.8-4 g. The rectal administration composition containing tamsulosin can overcome the defects of poor curative effect and great toxic or side effect in oral administration and systemic injection administration, and the defects of great side effect and poor patient dependence in partial injection administration, and can prolong the duration of drug actions, thereby providing a better treatment means for medical care personnel and patients. The production technology is simple and suitable for industrial mass production.

The invention relates to a preparation method of tamsulosin hydrochloride, which comprises the following steps: reacting R-(-)-5-(2-aminopropyl)-2-metoxybenzsulfamide hydrochloride and o-ethoxylphenoxylethyl bromide to obtain R-tamsulosin free alkali, and reacting the free alkali with hydrochloric acid to obtain the R-tamsulosin hydrochloride. The invention is characterized in that the reaction of the R-(-)-5-(2-aminopropyl)-2-metoxybenzsulfamide hydrochloride and o-ethoxylphenoxylethyl bromide is carried out in a water-containing solvent.

The invention provides a novel tamsulosin hydrochloride osmotic pump controlled-release tablet. Ethyl cellulose and povidone are used as membrane forming materials of a semipermeable membrane, and the asymmetric tablet form is preferably selected, so that the ageing of the semipermeable membrane can be avoided, and the drug residues can be reduced. The invention also provides a method for improving the ageing resistance of the tamsulosin hydrochloride osmotic pump controlled-release tablet, wherein the method is characterized in that the ethyl cellulose-povidone are used as the membrane forming materials of the semipermeable membrane. In addition, the invention also provides applications of the ethyl cellulose-povidone composition in preparing the anti-ageing tamsulosin hydrochloride osmotic pump controlled-release tablet.

The present invention discloses a tamulosin osmotic pump type controllably-released tablet preparation and its preparation method. Said preparation is composed of double-layer table core, semipermeable film with small pres and moisture-proof film. Its double-layer table core is formed from medicine-containing layer and assistant layer, in which the medicine-containing layer contains 10-99% of ethylene pyrrolidone polymer and/or ethylene pyrrolidone copolymer, and the assistant layer contains 10-80% of water-insoluble polymer, at the same time, in the assistant layer 10-80% of hydrophilic polymer with osmotic activity and 5-50% of osmotic pressure accelerator are contained.

The invention relates to a slow/controlled-release preparation of tamsulosin hydrochloride and a preparation method thereof. The slow/controlled-release preparation comprises (i) a pill core which ismade of the following raw material in parts by weight: 135-165 parts of a microcrystal cellulose micro-pill cores; (ii) a slow-release layer which is made of the following raw materials in parts by weight: 0.36-0.44 parts of tamsulosin hydrochloride, 145-200 parts of a slow/controlled release material and 3.8-58 parts of a pore forming agent. Dissolution degree tests show that the slow/controlled-release tamsulosin hydrochloride preparation consisting of a blank pill core and a medicine-carrying slow/controlled release coating layer has a slow-release effect within a relatively pH value range(the pH value is 1.2, 4 or 6.8), has a pH value independent slow-release property, and is capable of solving the problem that absorption of tamsulosin hydrochloride is affected as the pH value of a gastrointestinal tract is changed if a patient takes foods, therefore, the slow/controlled-release preparation of the tamsulosin hydrochloride, which is provided by the invention, can be taken both before or after a meal, and is relatively convenient to take, and absorption of the tamsulosin hydrochloride is not affected.

Belonging to the field of medicines, the invention particularly relates to a preparation method of a sustained release tablet containing tamsulosin hydrochloride. The dosage form is an oral preparation that is prepared by taking tamsulosin hydrochloride as an active component and using acceptable auxiliary materials in an orally disintegrating tablet. The preparation not only has the characteristics of rapid disintegrating speed, rapid onset, and high patient compliance of orally disintegrating tablets, but also has the advantages of long action time, significantly reduced adverse reactions during instantaneous release of drugs, and stable blood concentration.

The invention relates to a tamsulosin hydrochloride sustained-release pellet. The tamsulosin hydrochloride sustained-release pellet comprises a medicine-containing pellet body and a coating layer, wherein the coating layer wraps the medicine-containing pellet body, the medicine-containing pellet body comprises tamsulosin hydrochloride, a blank pellet core, a filling agent, a lubricating agent and an adhering agent, and the coating layer comprises Eudragit NE30D and talcum powder. A preparation method comprises the following steps: 1, preparing materials; 2, mixing; 3, preparing the adhering agent; 4, pelleting; 5 preparing a coating agent; 6, coating; 7, filling; and 8, packaging by aluminum-plastic for obtaining a finished product. The tamsulosin hydrochloride sustained-release pellet is suitable for the symptoms such as urination disorder caused by benign prostatic hyperplasia, and is good in drug release stability, small in irritation to the gastrointestinal tract, good in bioavailability, convenient to package, transport and store, and suitable for industrial production. The tamsulosin hydrochloride sustained-release pellet is good in absorption after oral medication, and although the tamsulosin hydrochloride sustained-release pellet can be taken on an empty stomach or after the meal, food can increase the total absorptive amount of the tamsulosin hydrochloride sustained-release pellet.

The invention discloses tamsulosin hydrochloride sustained-release pellets and a preparation method thereof. The tamsulosin hydrochloride sustained-release pellets comprise a coating layer, medicine-containing pellets, Eudragit NE-30D, powdered steatile, sodium dodecyl sulfate or polyethylene glycol; tamsulosin hydrochloride, blank pellets, a filler, a lubricant and an adhesive. The method employs a novel sustained release preparation and a pellets preparation, slow release means delay of drug release rate of the medicine from a dosage form, absorption rate of medicine in the body can be reduced, more stable treatment effect can be realized; pellets can increase the distribution area of the medicine on the surface of the gastrointestinal tract, irritation is reduced, bioavailability is increased, influence due to stomach evacuation factors is not generated, medicine can be uniformly absorbed in the body, individual difference is little, and simultaneous application of two advanced technologies enhances the technical advantage of the tamsulosin hydrochloride sustained-release pellets.

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a tamsulosin hydrochloride crystal form, which comprises the following steps: adding tamsulosin into a solvent, conducting heating to a first temperature, and conducting complete dissolving to obtain a first solution; adding an acid into the first solution, and carrying out heat preservation reaction at a first temperature to obtain a second solution; cooling the second solution to a second temperature, and conducting stirring for reaction to obtain a third solution; and filtering thethird solution and conducting drying to obtain the tamsulosin hydrochloride crystal form. The preparation method is simple in process, high in yield, high in product purity and suitable for large-scale industrial production.

The invention relates to a tamsulosin hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the tamsulosin hydrochloride film-controlled slow-release pellet utilizes Eurdragit NE30D and HPMC E5 as film-formation materials. A pellet core of the tamsulosin hydrochloride film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose and lactose as fillers, and polysorbate 80 as a solubilizer; and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit NE30D, HPMC E5 and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit NE30D to HPMC E5 to talcum powder is 30: 2: 4 and a film weight increasing ratio is in a range of 19 to 36%. The tamsulosin hydrochloride film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the tamsulosin hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the tamsulosin hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention discloses a suppository for treating prostatitis and a preparation method thereof. The suppository is prepared from the following raw material drugs in parts by weight: 0.3 to 0.5 part of tamsulosin Hydrochloride, 5 to 15 parts of golden cypress, 5 to 15 parts of common andrographis herb, 0.4 to 1 part of dragon blood, and 100 parts of 36 type mixed fatty acid glyceride. The suppository is administrated from the anus, and is pushed into rectum for half finger; the dosage of the suppository for an adult is 5 to 8g per time and the suppository is taken 1 to 2 times everyday, 30 continuously administrated days are taken as a course of treatment, and the total effective rate in 30 cases with chronic prostatitis treated with the suppository for one course of treatment is 94.8 percent.